Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia
Sign Up to like & getrecommendations! Published in 2019 at "Cellular and Molecular Life Sciences"
DOI: 10.1007/s00018-019-03054-z
Abstract: Medial vascular calcification has emerged as a putative key factor contributing to the excessive cardiovascular mortality of patients with chronic kidney disease (CKD). Hyperphosphatemia is considered a decisive determinant of vascular calcification in CKD. A… read more here.
Keywords: signaling pathways; vascular calcification; vascular smooth; calcification ... See more keywords
Phosphate Metabolism
Sign Up to like & getrecommendations! Published in 2020 at "Calcified Tissue International"
DOI: 10.1007/s00223-020-00727-x
Abstract: For a long time, phosphate, the anion that incorporates the element phosphorus, has been considered of minor relevance compared to its most studied parent calcium. However, the interest in phosphate metabolism has been remarkably increased… read more here.
Keywords: phosphate metabolism; congenital diseases; hyperphosphatemia; mechanisms underlying ... See more keywords
Hyperphosphatemia is associated with cardiac valve calcification in chronic hypoparathyroidism
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Endocrinological Investigation"
DOI: 10.1007/s40618-022-01770-1
Abstract: To evaluate the association between metabolic abnormalities and cardiovascular risk factors in patients with chronic hypoparathyroidism (HPP). Patients 18 years and older, glomerular filtration > 30 mL/min/1.73 m2 and no documented coronary artery disease were selected. Serum… read more here.
Keywords: risk; hyperphosphatemia; cardiovascular risk; cardiac valve ... See more keywords
Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.
Sign Up to like & getrecommendations! Published in 2020 at "Bone"
DOI: 10.1016/j.bone.2020.115300
Abstract: Hypophosphatasia (HPP) is the inborn-error-of-metabolism caused by loss-of-function mutation(s) of the ALPL gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). TNSALP in healthy individuals is on cell surfaces richly in bone, liver, and… read more here.
Keywords: hypophosphatasia; fgf23 sfrp4; hyperphosphatemia low; hyperphosphatemia ... See more keywords
Adsorptivity of cationic cellulose nanocrystals for phosphate and its application in hyperphosphatemia therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Carbohydrate polymers"
DOI: 10.1016/j.carbpol.2020.117335
Abstract: Nanocellulose has gained much attention because of its excellent properties. Cationic cellulose nanocrystals (cCNC) shows good adsorptivity toward negative ions and molecules. Phosphate binders are most used to treat hyperphosphatemia and it is significant to… read more here.
Keywords: cationic cellulose; phosphate; hyperphosphatemia; hyperphosphatemia therapy ... See more keywords
Npt2a as a target for treating hyperphosphatemia
Sign Up to like & getrecommendations! Published in 2022 at "Biochemical Society Transactions"
DOI: 10.1042/bst20211005
Abstract: Hyperphosphatemia results from an imbalance in phosphate (Pi) homeostasis. In patients with and without reduced kidney function, hyperphosphatemia is associated with cardiovascular complications. The current mainstays in the management of hyperphosphatemia are oral Pi binder… read more here.
Keywords: kidney; hyperphosphatemia; npt2a target; target treating ... See more keywords
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2021.1978973
Abstract: INTRODUCTION Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations. Sucroferric oxyhydroxide is an iron-based phosphate binder… read more here.
Keywords: treatment hyperphosphatemia; hyperphosphatemia; sucroferric oxyhydroxide; safety ... See more keywords
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2044472
Abstract: ABSTRACT Introduction Hyperphosphatemia is an inevitable complication for patients undergoing dialysis, as is the resulting need for treatment with phosphate binders. Currently, various phosphate binders are clinically available. In addition to their phosphate-lowering activity, individual… read more here.
Keywords: phosphate; hyperphosphatemia; safety profiles; treatment ... See more keywords
An update on tenapanor to treat hyperphosphatemia.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.1.3343689
Abstract: Hyperphosphatemia is a common feature in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease (ESRD). Commonly, high serum phosphate levels are observed only in later stages of CKD. The control… read more here.
Keywords: phosphate; phosphate levels; update tenapanor; hyperphosphatemia ... See more keywords
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Society of Nephrology : JASN"
DOI: 10.1681/asn.2015111266
Abstract: αKlotho (αKL) regulates mineral metabolism, and diseases associated with αKL deficiency are characterized by hyperphosphatemia and vascular calcification (VC). αKL is expressed as a membrane-bound protein (mKL) and recognized as the coreceptor for fibroblast growth… read more here.
Keywords: null mice; vascular calcification; ckl; hyperphosphatemia vascular ... See more keywords
Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: A cross-sectional study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2023.1142013
Abstract: Background Hyperphosphatemia remains a major complication in patients with Continuous ambulatory peritoneal dialysis (CAPD) leading to increased morbidity and mortality. However, phosphorus management still has many challenges. Objective This study aimed to investigate the prevalence… read more here.
Keywords: continuous ambulatory; ambulatory peritoneal; peritoneal dialysis; hyperphosphatemia ... See more keywords